Former U.S. Congressman Curt Weldon to Represent Regenicin
at 2011 Future of Financial Markets Conference in Mumbai
Former U.S. Congressman Curt Weldon to Represent Regenicin01/20/2011at 2011 Future of Financial Markets Conference in Mumbai
LITTLE FALLS, NJ -- (MARKET WIRE) -- 06/08/11 -- Regenicin, Inc. (OTCBB: RGIN) announces it is in advanced discussions with various developers in the State of Florida to determine the best strategic location and partners for the company to establish its research facilities. Sites presently being considered are world-class research and technology parks, which will allow Regenicin to collaborate with leading centers of excellence in the academic, research, and healthcare arenas.
The company is pursuing opportunities to lease new facilities that will not only accommodate the company's present needs for state-of-the-art lab space, but will also address the projected growth needs the company envisions as it executes its business plan.
return to 2011 Press and News Releases
return to Home Page
About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.
Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.